Bionano Genomics (NASDAQ:BNGO) announced its earnings results on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02), Fidelity Earnings reports.
BNGO stock opened at $0.52 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 0.30. Bionano Genomics has a twelve month low of $0.25 and a twelve month high of $1.39. The business has a 50 day moving average price of $0.56 and a two-hundred day moving average price of $0.56. The company has a market cap of $79.36 million, a price-to-earnings ratio of -0.27 and a beta of 1.59.
A number of equities research analysts recently issued reports on the company. Maxim Group assumed coverage on Bionano Genomics in a research report on Monday, August 17th. They issued a “buy” rating and a $2.00 target price on the stock. Zacks Investment Research upgraded Bionano Genomics from a “sell” rating to a “hold” rating in a research note on Monday, October 26th. LADENBURG THALM/SH SH initiated coverage on Bionano Genomics in a research note on Thursday, September 24th. They issued a “buy” rating and a $1.25 price target for the company. Finally, Oppenheimer restated a “buy” rating on shares of Bionano Genomics in a research note on Monday, August 24th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $1.30.
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.